Top Companies in Pharmaceutical Contract Manufacturing Market

The global pharmaceutical contract manufacturing market is projected to reach USD 311.95 billion by 2030 from USD 209.90 billion in 2025, at a CAGR of 8.2% from 2025 to 2030. The expected growth can be credited to the GLP-1 capacity crunch, continuing approvals for ADCs, and the loss of exclusivity of blockbuster biologics.

Several key players in the pharmaceutical contract manufacturing industry with a strong global footprint include Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), WuXi AppTec (China), WuXi Biologics (China), AbbVie Inc. (US), Catalent, Inc. (US), Samsung Biologics (South Korea), Evonik (Germany), FUJIFILM Holding Corporation (Japan), Siegfried Holding AG (Switzerland), and Boehringer Ingelheim International GmbH (Germany). Other notable companies are Merck KGaA (Germany), Almac Group (UK), Charles River Laboratories (US), Asychem Inc. (China), Vetter (Germany), and Alcami Corporation (US). Companies in this sector employ various growth strategies to strengthen their international presence and reinforce market positions.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific Inc. has focused on adding fill finish capacities with the opening of a new sterile drug facility in Singapore in 2023 and the purchase of Sanofi’s New Jersey Fill Finish and Packaging plant in 2025. In March 204, Lonza strengthened its biologics manufacturing capacity by acquiring Roche’s Vacaville site for USD 1.2 billion, enhancing its role in the global pharmaceutical contract manufacturing market.

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific Inc. is a key player in the pharmaceutical contract manufacturing market, leveraging its extensive drug formulation and development capabilities. The company also launched its Accelerator Drug Development platform, offering an integrated suite of CDMO and CRO services to guide clients from pre-clinical stages through commercialization across small molecules, biologics, and advanced therapies. The company has also undertaken expansions in key manufacturing sites across Missouri, Ohio, Massachusetts, and North Carolina, ensuring scalable and flexible infrastructure to meet growing demand. These initiatives demonstrate Thermo Fisher’s commitment to advancing its end-to-end service capabilities, positioning it as a leading partner for pharmaceutical and biopharmaceutical companies worldwide.

Catalent, Inc. (Novo Holdings) (US)

Catalent is a well-established CDMO that delivers development solutions for medicines, biologics, consumer & animal health products, with sophisticated delivery methods. To satisfy the needs of the pharmaceutical and biotechnology sectors, the company presents several oral, injectable, and respiratory delivery systems. It also increased drug substance manufacturing capacity at its Madison facility, boosting flexibility for clinical and commercial production. These initiatives have strengthened the global capabilities of Catalent, enabling it to provide comprehensive, end-to-end services in drug development, manufacturing, and supply chain management for the pharmaceutical and biopharmaceutical industries.

Market Ranking

The pharmaceutical contract manufacturing market is highly fragmented, with the top five key players commanding a share of global revenues, estimated to be between 10% to 15% of the total market. These leading companies reinforce their market positions through strategic investments, regulatory advancements, and extensive partnerships. Notably, the leading global players include Thermo Fisher Scientific Inc. (US), Lonza Group (Switzerland), WuXi AppTec and WuXi Biologics (China), Catalent (US), and Samsung Biologics (South Korea). Thermo Fisher Scientific Inc. continues to expand its integrated capabilities through acquisitions, facility upgrades, and advanced drug development platforms covering small molecules, biologics, and cell and gene therapies. Lonza maintains a strong position with extensive biologics manufacturing capacity, strategic site acquisitions, and investment in innovative production technologies for complex biologics and advanced modalities.

WuXi AppTec and WuXi Biologics leverage a global network of facilities to deliver seamless services from discovery through commercial manufacturing, supported by proprietary technology platforms. Catalent, Inc. has strengthened its biologics, oral dosage, and clinical supply capabilities through targeted acquisitions and expansions in high-potency and advanced therapy manufacturing. Samsung Biologics continues to expand its large-scale biologics production footprint, enhance technology partnerships, and diversify into biosimilars and next-generation therapeutics. Collectively, these companies set the benchmark for technological innovation, scalability, and global service integration, positioning themselves as preferred partners for pharmaceutical and biopharmaceutical firms worldwide.

The remainder of the market, comprising approximately 85–90%, is populated by various regional players. These players are gaining ground through partnerships, collaborations, and technological innovation. Market shifts are driven by advances in pharmaceutical contract manufacturing, changing regulatory landscapes, and growing demand for non-invasive, personalized medicine.

Related Reports:

Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF - Parenteral, Tablet, Capsule), Biologics (API, FDF), Packaging & Labelling, Fill-finish), Molecule (Small, Large (ADC, CGT)) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com